

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

HDLM-2

RRID:CVCL_0009

Type: Cell Line

Proper Citation

RRID:CVCL_0009

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0009

Proper Citation: RRID:CVCL_0009

Description: Cell line HDLM-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hodgkin lymphoma

Defining Citation: [PMID:2602652](#), [PMID:2690233](#), [PMID:3713248](#), [PMID:8558920](#), [PMID:9685479](#), [PMID:12581897](#), [PMID:16957166](#), [PMID:17065008](#), [PMID:19380639](#), [PMID:20164919](#), [PMID:20628145](#), [PMID:22460905](#), [PMID:25894527](#), [PMID:27397505](#), [PMID:29533902](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HDLM-2

Synonyms: HD-LM-2, HDLM2

Cross References: CLO:CLO_0003671, CLDB:cl1580, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473364, BioSample:SAMN10988513, cancercellines:CVCL_0009, Cell_Model_Passport:SIDM01064, ChEMBL-Cells:ChEMBL3308234, ChEMBL-Targets:ChEMBL2366231, Cosmic:924110, Cosmic:988701, Cosmic:1013909, Cosmic:1086355, Cosmic:1278832, Cosmic:1289699, Cosmic:1290220, Cosmic:1432040,

Cosmic:2276322, Cosmic:2464309, Cosmic-CLP:924110, DepMap:ACH-000267, DSMZ:ACC-17, DSMZCellDive:ACC-17, EGA:EGAS00001000978, GDSC:924110, GEO:GSM335390, GEO:GSM381298, GEO:GSM499724, GEO:GSM499732, GEO:GSM552430, GEO:GSM646534, GEO:GSM887064, GEO:GSM888134, GEO:GSM1669870, GEO:GSM7701399, IARC_TP53:23613, IGRhCellID:HDLM2, LINCS_LDP:LCL-2007, PharmacoDB:HDLM2_521_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_0009, PubChem_Cell_line:CVCL_0009, Wikidata:Q54882175

ID: CVCL_0009

Record Creation Time: 20220427T220323+0000

Record Last Update: 20260913T004001+0000

Ratings and Alerts

No rating or validation information has been found for HDLM-2.

No alerts have been found for HDLM-2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. *Molecular cancer therapeutics*, 23(1), 68.

Archer S, et al. (2024) CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(8), 1595.

Hoseini SS, et al. (2021) T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. *Journal for immunotherapy of cancer*, 9(5).

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.